Male osteoporosis: Epidemiology, pathophysiology, diagnosis, prevention and treatment;L'ostéoporose masculine: Épidémiologie, physiopathologie, diagnostic, prévention et traitement

Revue de Medecine Interne

Volumn 25, Issue SUPPL. 5, 2004, Pages

  Blain, H ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Epidemiology; Male; Osteoporosis; Prevention; Risk factors; Treatment

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; PAMIDRONIC ACID; PARATHYROID HORMONE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; BODY MASS; BONE MASS; CALCIUM INTAKE; CHRONIC INFLAMMATION; CORTICOSTEROID THERAPY; DIAGNOSTIC PROCEDURE; FRAGILITY FRACTURE; HUMAN; HYPERCALCIURIA; HYPERTHYROIDISM; HYPOGONADISM; IMMOBILIZATION; MALE; OSTEOPOROSIS; REVIEW; RISK FACTOR; SMOKING; VITAMIN SUPPLEMENTATION;

EID: 14844303576     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(04)80054-7     Document Type: Article

References (73)

1. Mussolino M.E., Looker A.C., Madans J.I., Langlois J.A., and Orwoll E.S. Risk factors for hip fracture in white men: the NHAES I Epidemiologic Follow-up Study J Bone Miner Res 13 1998 918 924
2. Looker A.C., Orwoll E.S., Johnston M.L., Lindsay R.L., Wahner H.W., and Dunn W.L. Prevalence of low femoral bone density in older US adults from NHAES III J Bone Mineral Res 12 1997 1761 1768
3. Tenenhouse A., Joseph L., Kreiger N., Poliquin S., Murray T.M., and Blondeau Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA refe rence standard: the Canadian Multicentre Osteoporosis Study (CAMOS) Osteoporos Int 11 2000 897 904
4. Baudoin C., Fardellone P., Thelot B., Juvin R., Potard V., and Bean K. Hip fractures in France: the magnitude and perspective of the problem Osteopor Int S1 1996
5. Adachi J.D., Saag K.G., Delmas P.D., Liberman U.A., Emkey R.D., and Seeman E. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a rando mized, double-blind, placebo-controlled extension trial Arthritis Rheum 44 2001 202 211
6. Dennison E., and Cooper C. The epidemiology of osteoporosis Br J Clin Pract 50 1996 33 36
7. Jones G., Nguyen T., Sambrook P.N., Kelly P.J., Gilbert C., and Eisman J.A. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES) Osteoporos Int 4 1994 277 282
8. Sambrook P.N., Plillips S.R., Seeman E., and Ebeling P.R. Preventing osteoporosis: outcomes of the Australian Fracture Preventing Summit Med J Aust 176 2002 S1 S16
9. Orwoll E.S., Bevan L.N., and Phipps K.R. Determinants of bone mineral density in older men Osteoporos Int 11 2000 815 821
10. Gullberg B., Johnell O., and Kanis J.A. World-wide projections for hip fracture Osteoporos Int 7 1997 407 413
11. Adachi J.D., Ioannidis G., Pickard L., Berger C., Prior J.C., and Joseph L. The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Cana dian Multicentre Osteoporosis Study (CaMos) Osteoporos Int 14 2003 895 904
12. Levy P., Levy E., Audran M., Cohen-Solal M., Fardellone P., and Le Parc J.M. The cost of osteoporosis in men: the French situation Bone 30 2002 631 636
13. Baudoin C., Fardellone P., Bean K., Ostertag-Ezembre A., and Hervy H. Clinical outcomes and mortality after hip fractures: a 2-year follow-up study Bone 18 1996 149S
14. Cooper C. The crippling consequences of fractures and their impact on quality of life Am J Med 103 1997 125 195
15. Trombetti A., Herrmann F., Hoffmeyer P., Schurch M.A., Bonjour J.P., and Rizzoli R. Survival and potential years of life lost after hip fracture in men and age-matched women Osteoporos Int 13 2002 731 737
16. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., and Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 1999 878 882
17. Hasserius R., Karlsson M.K., Nilsson B.E., Redlund-Johnell I., and Johnell O. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year popula tion-based study of598 individuals from Swedish Cohort in the European Vertebral Osteoporosis Study Osteoporosis Int 14 2003 61 68
18. Kanis J.A., Oden A., Johnell O., De Laet C., Jonsson B., and Oglesby A.K. The components of excess mortality after hip fracture Bone 32 2003 468 473
19. Levy E. Cost analysis of osteoporosis related to untreated menopause Clin Rheumatol 8 1989 76
20. Bailey D.A., Martin A.D., McKay H.A., Whiting S., and Mirwald R. Calcium accretion in girls and boys during puberty: a longitudinal analysis J Bone Miner Res 15 2000 2245 2250
21. Seeman E. During aging, men lose less bone than women because they resorb less endosteal bone Calcified Tissue Int 69 2001 205 208
22. Beck T.J., Looker A.C., Ruff C.B., Sievanen H., and Wahner H.W. Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dualenergyx-ray absorptiometry data J Bone Miner Res 15 2000 2297 2304
23. Fatayerji D., and Eastell R. Age-related changes in bone turnover in men J Bone Miner Res 14 1999 1203 1210
24. Khosla S., Melton L.J. 3rd, Atkinson E.L., O'Fallon W.M., Klee G.G., and Riggs B.L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women J Clin Endocrinol Metab 83 1998 2266 2274
25. Marcus R., Leary D., Schneider D.L., Shane E., Favus M., and Quigley C.A. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome J Clin Endocrinol Metab 85 2000 1032 1037
26. Falahati-Nini A., Riggs B.L., Atkinson E.J., O'Fallon W.M., Eastell R., and Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 106 2000 1553 1560
27. Braidman I., Baris C., Wood L., Selby P., Adams J., and Freemont A. Preliminary evidence for impaired estrogen receptor-alpha protein expression in osteoblasts and osteocytes from men with idiopathic osteoporosis Bone 26 2000 423 427
28. Agnusdei D., Civitelli R., Camporeale A., Parisi G., Gennari L., and Nardi P. Age-related decline of bone mass and intestinal calcium absorption in normal males Calcif Tissue Int 63 1998 197 201
29. Orwell E.S., and Meier D.E. Alterations in calcium, vitamin D, and parathyroid hormone physiology in normal men with aging: relationship to the development of senileosteopenia J Clin Endocrinol Metab 63 1986 1262 1269
30. Blain H, Vuillemin A, Blain A, Guillemin F, De Talance N, DoucetB, et al. Age-related bone loss in men: evidence for hyperparathyroidism and insulin-like growth factor deficiency. J Geromol Med Sci (in press).
31. Lewiecki EM, Kendler DL, Kiebzak GM, Schmeer P, Prince RL, El-HajjFuleihan G, et al. Special report on the official positions of the International Society for Clinical Densitometry. Osteoporos Int (in press).
32. Felsen D.T., Kiel D.P., Anderson J.J., and Kannel W.B. Alcohol consumption and hip fractures: the Framingham study Am J Epidemiol 128 1988 1102 1110
33. Orwell E.S., and Klein R.F. Osteoporosis in men Endocr Rev 16 1995 87 116
34. Kiratli B.J., Srinivas S., Perkash I., and Terris M.K. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer Urology 57 2001 127 132
35. Bruder J.M., and Welsch M.D. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen deprivation J Bone Miner Res 17 2002 411
36. Baillie S.P., Davison C.E., Johnson F.J., and Francis R.M. Pathogenesis of vertebral crush fractures in men Age ageing 21 1992 139 141
37. Jackson J.A., and Spiekerman A.M. Testosterone deficiency is common in men with hip fracture after a falls Clin Res 37 1989 131 136
38. Orwell E.S., Scheele W.H., Paul S., Adami S., Syversen U., and Diez-Perez A. The effect of teriparatide [human parathyroid hormone (134)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 2003 9 17
39. Tanaka T., Latorre M.R., Jaime P.C., Florindo A.A., Pippa M.G., and Zerbini C.A. Risk factors for proximal femur osteoporosis in men aged 50 years or older. Osteoporos Int 12 2001 942 949
40. Ismail A.A., O'Neill T.W., Cooper C., and Silman A.J. European Vertebral Osteoporosis Study Group. Risk factors for vertebral deformities in men: relationship to number of vertebral deformities J Bone Miner Res 15 2000 278 283
41. Ward K.D., and Klesges R.C. A meta-analysis of the effects of cigarette smoking on bone mineral density Calcif Tissue Int 68 2001 259 270
42. Kelly P.J., Pocock N.A., Sambrook P.N., and Eisman J.A. Dietary calcium, sex hormones, and bone mineral density in men BMJ 300 1990 1361 1364
43. Vuillemin A., Guillemin F., Jouanny P., Denis G., and Jeandel C. Differential influence of physical activity on lumbar spine and femoral neck bone mineral density in the elderly population J Gerontol Med Sci 56 2001 B248 B253
44. Kaufman J.M., Johnell O., Abadie E., Adami S., Audran M., and Avouac B. Background for the studies on the treatment of male osteoporosis: state of the art Ann Rheum Dis 59 2000 765 772
45. Brown J.P., and Josse R.G. Scientific Advisory Council, Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada CMAJ 167 2002 S1 S34
46. Dawson-Hughes B., Harris S.S., Krall E.A., and Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 337 1997 670 676
47. Nguyen T.V., Center J.R., and Eisman J.A. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass J Bone Miner Res 15 2000 322 331
48. Trivedi D.P., Doll R., and Khaw K.T. Effect of four monthly oral vitamin D (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial BMJ 326 2003 469
49. Kujala U.M., Kaprio J., Kannus P., Sarna S., and Koskenvuo M. Physical activity and osteoporotic hip fracture risk in men Arch Intern Med 160 2000 705 708
50. Diamond T., Sambrook P., Williamson M., Flicker L., Nowson C., and Fiatarone-Singh M. Guidelines for the treatment of osteoporosis in men for general practitioners Aust Fam Physician 30 2001 787 791
51. Orwell E., Ettinger M., Weiss S., Miller P., Kendler D., and Graham J. Alendronate for the treatment of osteoporosis in men N Engl J Med 343 2000 604 610
52. Ringe J.D., Faber H., and Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study J Clin Endocrinol Metab 86 2001 5252 5255
53. Ringe J.D., Dorst A., and Faber H. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two arm study Rheumatol Int 24 2004 110 113
54. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., and Cooper C. Use of oral corticosteroids and risk of fractures J Bone Miner Res 15 2000 993 1000
55. Wallach S., Cohen S., Reid D.M., Hughes R.A., Hosking D.J., and Laan R.F. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif Tissue Int 67 2000 277 285
56. Reid D.M., Adami S., Devogelaer J.P., and Chines A.A. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy Calcif Tissue Int 69 2001 242 247
57. Boutsen Y., Jamart J., Esselinckx W., Stoffel M., and Devogelaer J.P. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial Calcif Tissue Int 61 1997 266 271
58. Diamond T., Campbell J., Bryant C., and Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma Cancer 83 1998 1561 1566
59. Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., and Schoenfcld D.A. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer N Engl J Med 345 2001 948 955
60. Diamond T.H., Winters J., Smith A., De Souza P., Kersley J.H., and Lynch W.J. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen bloc kade. A double blind, randomised, placebo-controlled crossover study Cancer 92 2001 1444 1450
61. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
62. Zacharin M.R., Pua J., and Kanumakala S. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male osteoporosis Clin Endocrinol 58 2003 691 695
63. Snyder P.J., Peachey H., Hannoush P., Berlin J.A., Loh L., and Lenrow D.A. Effect of testosterone treatment on bone mineral density in men over 65 years of age J Clin Endocrinol Metab 84 1999 1966 1972
64. Snyder P.J., Peachey H., Berlin J.A., Hannoush P., Haddad G., and Dlewati A. Effects of testosterone replacement in hypogonadal men J Clin Endocrinol Metab 85 2000 2670 2677
65. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., and Diez-Perez A. Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone density J Bone Miner Res 16 2001 162
66. (ahead of print) Kaufman J.M., Orwell E., Goemaere S., San Martin J., Hossain A., and Dalsky G.P. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy Osteoporos Int 2004
67. (ahead of print) Kurland E.S., Heller S.L., Diamond B., McMahon D.J., Cosman F., and Bilezikian J.P. The importance of bisphosphonate therapy in maintaining bone mass after therapy with teriparatide [human parathyroid hormone (1-34)] Osteoporos Int 2004
68. Ringe J.D., Dorst A., Kipshoven C., Rovati L.C., and Setnikar I. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittentmonofluorophosphate Osteoporos Int 8 1998 47 52
69. Ringe J.D., and Rovati L.C. Treatment of osteoporosis in men with fluoride alone or in combination with bisphophonates Calcif tissue Int 69 2001 252 255
70. Reginster J.Y., Lecart M.P., Deroisy R., and Lousberg C. Strontium ranelate: a new paradigm in the treatment of osteoporosis Expert Opin Investig Drugs 13 2004 857 864
71. Gowen M., Stroup G.B., Dodds R.A., James I.E., Votta B.J., and Smith B.R. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats J Clin Invest 105 2000 1595 1604
72. Melton L.J. 3rd, Atkinson E.J., Cooper C., O'Fallon W.M., and Riggs B.L. Vertebral fractures predict subsequent fractures Osteoporos Int 10 1999 213 221
73. Olszynski W.P., Davison S., Adachi J.D., Brown J.P., Cummings S.R., and Hanley D.A. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment Clin Ther 26 2004 15 27